Business Context and Reporting Period
This Form 6-K filing by China SXT Pharmaceuticals, Inc. covers the month of July 2026. The report discloses the entry into a Material Definitive Agreement involving a securities purchase agreement with an institutional investor to raise capital for working capital and corporate purposes.
Key Financial Metrics and Transaction Details
- Commitment Amount: Up to $30,000,000 in aggregate pre-paid purchases.
- Initial Closing: $3,150,000 principal amount expected on July 6, 2026.
- Original Issue Discount (OID): $150,000 on the initial purchase; 5% on subsequent purchases.
- Interest Rate: 7% per annum on subsequent pre-paid purchases, payable quarterly.
- Default Interest: Accelerated repayment at the lesser of 18% per annum or the maximum rate permitted by law.
- Placement Fees: 4.5% cash fee plus 0.5% non-accountable expense reimbursement to Univest Securities, LLC.
- Expense Cap: Reimbursement of out-of-pocket expenses capped at $50,000.
Material Changes and Transaction Structure
The Company entered into a Securities Purchase Agreement on July 3, 2026, allowing for an initial funding followed by additional requests up to the $30 million commitment over a two-year period. Subsequent purchases must be between $250,000 and $3,000,000. The agreement includes a conversion feature where the investor may purchase Class A ordinary shares at a price equal to 50% of the lower of the market closing price on the signing date or the lowest closing price during the preceding 180 trading days, subject to a floor price of $0.20 per share.
Guidance, Risks, and Contingencies
- Use of Proceeds: Working capital and other corporate purposes.
- Registration: The Company will file a Form F-3 registration statement within 45 days of the closing date to register the resale of shares.
- Ownership Limit: The investor's right to purchase shares is limited to the funded amount and 9.99% beneficial ownership of outstanding Class A shares.
- Risk of Default: In the event of default, the investor may accelerate repayment of the outstanding balance with increased interest.
- Regulatory Status: The offering relies on an exemption from registration under Regulation D.
Investor Verification Checklist
- Verify the actual closing date and receipt of the initial $3,150,000 principal.
- Confirm the filing of the Form F-3 registration statement within the 45-day window.
- Monitor the Company's stock price relative to the $0.20 floor price and the 50% discount conversion mechanism.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific default conditions.
- Assess the impact of the 7% interest accrual and potential dilution on future financial statements.